Injectsense launched a new medical device chronic continuous IOP monitoring system for glaucoma patients. The IOP Connect™ system consists of a sensor which is smaller than the size of a rice grain which can be easily delivered to the eye by injection during a five-minute in-office procedure.
In today’s world, ophthalmologists lack in knowing how an individual IOP differs over a 24-hour period. IOP of an individual varies significantly during the day, especially at night with physical activity. Ophthalmologists thus require a device which can be placed in the eye to monitor IOP, day and night, continuously for the lifetime of a patient.
A continuous IOP monitoring system designed with a digital health framework will offer chronic continuous IOP monitoring thus enabling doctors for the first time to access clinical IOP data for 4 million US patients between office visits. Being different from other sensors, the Injectsense device eventually reduces patient intervention through its autonomous data collection.
It can be positioned in the eye to monitor IOP, day and night, regularly for the lifetime of a patient by allowing clinicians to better measure compliance and the effectiveness of every glaucoma therapy, enhancing outcomes.
US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for chronic continuous IOP monitoring system for glaucoma patients.
